Please provide your email address to receive an email when new articles are posted on . When administered within 4 to 5 hours of stroke onset, the thrombolytic drug alteplase significantly increased ...
Please provide your email address to receive an email when new articles are posted on . Treatment with tenecteplase in an Australian mobile stroke unit was safe and resulted in improved outcomes ...
A noninferiority trial comparing two doses of thrombolytic therapy with the tissue plasminogen activator (tPA) alteplase has failed to demonstrate that low-dose therapy is as effective as ...
The researchers observed no significant differences between tenecteplase and alteplase in terms of effectiveness or safety outcomes for the overall cohort after adjustment for covariates. HealthDay ...
Researchers found that the percentage of patients with functional independence at 90 days was higher in the alteplase group vs the standard treatment group. HealthDay News — For patients with mainly ...
Before 1998, urokinase was considered standard therapy for the management of occluded hemodialysis catheters. The dose of 5000 units per port appears on the FDA-approved labeling for urokinase. Bolus ...
TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...
LOS ANGELES -- Tenecteplase (TNKase) is a more powerful thrombolytic for large vessel acute ischemic stroke than alteplase (Activase) but just as safe, the EXTEND-IA TNK trial showed. Tenecteplase ...
Review the side-effects of Alteplase as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...
The bolus thrombolytic, tenecteplase, was non-inferior to alteplase, which is given by a bolus followed by an infusion, for functional outcomes in acute ischemic stroke patients treated within 4½ ...
Safe and Cost Effective Use of Alteplase for the Clearance of Occluded Central Venous Access Devices
Phase I and Pharmacologic Study of Oral ZD9331, A Novel Nonpolyglutamated Thymidylate Synthase Inhibitor, in Adult Patients With Solid Tumors PURPOSE: To determine whether cryopreserved solutions of ...
The manufacturer carried out a systematic literature search, which was based on a previously published Cochrane review ('Thrombolysis for acute ischaemic stroke'), but restricted the search to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results